Molecular Templates, Inc. – Non-Hodgkin’s B-cell Lymphoma

Access Program Information

This is an active treatment, extended access study open solely to those subjects who have
successfully completed the Core and Repeat Dosing portions of the MT-3724_NHL_001_US
clinical study and who, in the investigator’s judgment, (i) have not had progressive disease
while on MT-3724 treatment (i.e.; have shown a complete or partial response or stable
disease), (ii) have experienced no clinical or laboratory toxicities that would
contraindicate further MT-3724 dosing and (iii) have no acceptable and better alternative
treatment available to them.

Rare Disease: